Moolec Science (MLEC) Preferred Stock Liabilities (2023 - 2024)
Moolec Science's (MLEC) quarterly Preferred Stock Liabilities came in at $3068.0 in Q3 2024, little changed year-on-year from $3068.0 in Q4 2023, and little changed quarter-over-quarter from $3068.0 in Q2 2024.
Moolec Science (MLEC) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Moolec Science has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $3068.0 for Q3 2024.
- Preferred Stock Liabilities for Q3 2024 came in at $3068.0, changed 0.0% year-over-year; the trailing twelve-month figure through Sep 2024 was $3068.0 (changed 0.0% YoY), and the FY2024 annual result was $3068.0, changed 0.0% from the prior year.
- Preferred Stock Liabilities came in at $3068.0 for Q3 2024 at Moolec Science, roughly flat from $3068.0 in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $3068.0 in Q2 2023 to a low of $3068.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Moolec Science | 6.98 Bn | 6.98 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 3,068.00 |
| Jun 30, 2024 | 3,068.00 |
| Mar 31, 2024 | 3,068.00 |
| Dec 31, 2023 | 3,068.00 |
| Sep 30, 2023 | 3,068.00 |
| Jun 30, 2023 | 3,068.00 |